Publications by authors named "N Hatakeyama"
We herein describe a patient with non-small-cell lung cancer who achieved pCR with a single dose of pembrolizumab-based chemoimmunotherapy followed by surgery. A 61-year-old man was referred to our hospital with wheezing and an abnormal chest shadow. Squamous cell carcinoma of the left lower lobe, cT2aN1M0 stage IIB, was diagnosed and pembrolizumab-based chemoimmunotherapy was initiated at the patient's request.
View Article and Find Full Text PDFArticle Synopsis
- Donanemab is a monoclonal antibody that showed effectiveness and safety in treating early-stage Alzheimer's disease (AD) in a trial involving Japanese patients among others.
- In the TRAILBLAZER-ALZ 2 trial with 1,736 participants, Japanese participants (88 total) received either donanemab or a placebo, with results measured over 76 weeks.
- Results indicated that donanemab slowed disease progression significantly compared to placebo, with 83.3% of treated patients showing a reduction in amyloid plaques, though some experienced amyloid-related side effects.
Background: An increased relative eosinophil count (REC) has potential as a predictive biomarker for a beneficial clinical response and outcome to cancer immunotherapies. Therefore, the present study investigated the impact of an increased posttreatment REC on the prognosis of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).
Methods: We retrospectively reviewed all 151 patients diagnosed with NSCLC and treated with ICI monotherapy and blood test data between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.
Background: The peripheral blood eosinophil count prior to treatment has potential as a predictive biomarker for a beneficial clinical response to cancer immunotherapies. Therefore, the present study investigated the impact of the eosinophil count on overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI).
Methods: We retrospectively reviewed all patients diagnosed with NSCLC and treated with ICI monotherapy between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.
Article Synopsis
- A study was conducted to determine if administering granulocyte colony-stimulating factor (G-CSF) before assisted reproductive technology (ART) could improve embryo development and pregnancy rates in women with poor ovarian reserve.
- The trial included 100 women aged 20 to 42, where one group received G-CSF injections and the other did not; results showed that the G-CSF group had significantly higher fertilization, embryonic development, and pregnancy rates compared to controls.
- The cumulative live birth rate was 32% in the G-CSF group, compared to 14% in the control group, and infants born from the G-CSF group showed no congenital anomalies, indicating a positive association